risperidone IR and LAI formulation
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychotic Disorders
Conditions
Psychotic Disorders, Schizophrenia
Trial Timeline
Dec 1, 2008 → Jun 1, 2009
NCT ID
NCT00821600About risperidone IR and LAI formulation
risperidone IR and LAI formulation is a phase 1 stage product being developed by Johnson & Johnson for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00821600. Target conditions include Psychotic Disorders, Schizophrenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00821600 | Phase 1 | Completed |
Competing Products
14 competing products in Psychotic Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine, Amantadine + Olanzapine and placebo | Eli Lilly | Phase 1 | 33 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine + olanzapine + risperidone | AstraZeneca | Pre-clinical | 23 |
| Asenapine 5-20 mg daily + Placebo 1-4 tablets daily | Merck | Approved | 85 |
| Ziprasidone HCL (oral) | Pfizer | Approved | 84 |
| Aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Risperidone/Quetiapine | Bristol Myers Squibb | Pre-clinical | 22 |
| mifepristone + placebo | Corcept Therapeutics | Phase 3 | 72 |
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Fluvoxamine | Corcept Therapeutics | Phase 1 | 28 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |